

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 21, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933**

**Enanta Pharmaceuticals, Inc.**

**File No. 333-184779 - CF#28829**

---

Enanta Pharmaceuticals, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on November 6, 2012, as amended.

Based on representations by Enanta Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through February 5, 2016
Exhibit 10.2	through February 5, 2016
Exhibit 10.3	through March 30, 2014

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jennifer Riegel  
Special Counsel